SCHEDULE: Crystal Peak Investment Acquires Controlling Stake in LakeShore Biopharma with $15 Million Private Placement

Crystal Peak Investment Inc., along with its affiliates, has acquired a 51% beneficial ownership stake in LakeShore Biopharma Co., Ltd. through a $15 million private placement and subsequent warrant exercise.

Summary

• Crystal Peak Investment Inc. purchased 16,987,542 Ordinary Shares of LakeShore Biopharma Co., Ltd. at US$0.883 per share for a total cash consideration of US$15 million in a private placement.
• As additional consideration for the investment, 16,987,542 warrants were issued to Crystal Peak Investment Inc., each entitling the holder to purchase one Ordinary Share at an exercise price of US$1.079.
• Crystal Peak Investment Inc. fully exercised these warrants on a cashless basis on July 11, 2025, resulting in the issuance of an additional 4,033,790 Ordinary Shares.
• The combined transactions give Crystal Peak Investment Inc., Crystal Peak Holdings Inc., and Huaqin Xue beneficial ownership of 21,021,332 Ordinary Shares, representing 51.0% of LakeShore Biopharma's total issued Ordinary Shares as of July 11, 2025.
• The funds for the private placement were sourced from the personal funds of Huaqin Xue, who is the sole shareholder of Crystal Peak Holdings Inc. and a director of both Crystal Peak Investment Inc. and Crystal Peak Holdings Inc.
• Proceeds from the sale are designated for LakeShore Biopharma's operations, core business development and expansion, working capital replenishment, and other general corporate purposes, requiring Crystal Investment's prior written approval for other uses.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital injection and a strong vote of confidence from a major investor taking a controlling stake. While there's dilution and some control ceded, the overall sentiment is positive due to the secured funding for operations and growth, which is crucial for a biopharma company.

Positives

• LakeShore Biopharma secured US$15 million in cash, providing a significant capital injection for its operations, core business development, and working capital.
• The investment indicates a strong commitment and potential for strategic alignment from a major investor, Crystal Peak Investment, which now holds a controlling 51.0% stake.
• The company has agreed to make public information available and file requisite SEC reports to permit future sales under Rule 144, which could improve liquidity for the investor.

Negatives

• The shares were purchased at US$0.883 per share, representing a 10% discount to the lower of the 10-day volume-weighted average price or the closing price on the trading day preceding the agreement date, which could indicate a less favorable valuation for existing shareholders.
• The issuance of 16,987,542 warrants, even at a 10% premium to the previous day's closing price, could lead to future dilution for existing shareholders if fully exercised.
• LakeShore Biopharma is obligated to pay US$100,000 to the Purchaser for due diligence and legal fees, reducing the net proceeds from the capital raise.
• The Purchaser has significant control over the use of proceeds, requiring prior written approval for purposes other than core operations, which may limit management's strategic flexibility.

Risks

• Potential future dilution for existing shareholders from the exercise of the issued warrants.
• Restrictions on the use of proceeds, requiring prior written approval from Crystal Investment for non-core business purposes, which could impact the company's operational agility.
• The company's ability to maintain compliance with Nasdaq listing requirements is crucial, and any non-compliance could negatively impact share value.
• The 40-day distribution compliance period for the purchased shares and warrants restricts immediate resale by the Purchaser within the U.S. or to U.S. Persons.
• The company is subject to various laws and regulations, and non-compliance could lead to Material Adverse Effects on its business or financial condition.

Future Outlook

The company intends to use the proceeds from the private placement for its operations, the development and expansion of its core business, replenishment of working capital, and other general corporate purposes. The Reporting Persons intend to continue reviewing their investments in the Issuer and may acquire or dispose of additional securities based on factors such as current and anticipated trading prices, the financial condition and prospects of the Issuer, and general economic conditions.

Management Comments

• The Issuer has agreed that it shall use the proceeds from the sale of the Shares and Warrants for its operations, the development and expansion of its core business, the replenishment of working capital, and other general corporate purposes, and may not use the proceeds for other purposes without the prior written approval of Crystal Investment.
• Crystal Investment acquired the Shares and Warrants for its own account for investment purposes only and not with the view to, or with any intention of, resale, distribution, or other disposition thereof.

Industry Context

This filing indicates a significant private equity investment into a biopharma company, which is a common strategy for growth-stage companies in the life sciences sector to secure capital for research and development, clinical trials, and market expansion without immediate public market pressures. The acquisition of a controlling stake by an investment firm suggests a long-term strategic interest in the company's core business and future potential, aligning with trends of private capital flowing into promising biotech ventures.

Comparison to Industry Standards

• The acquisition of a controlling stake (51%) by an investment firm is a common strategy in the biopharma sector for private equity or strategic investors seeking to exert significant influence over company direction and unlock value. This is comparable to private equity buyouts or significant strategic investments seen in smaller biotech firms acquired by larger funds or pharmaceutical startups receiving substantial growth funding.
• The pricing of the shares at a discount and warrants at a premium is a typical structure in private placements, balancing immediate capital infusion with future potential dilution and investor upside. This structure is often observed in Private Investment in Public Equity (PIPE) deals, where institutional investors provide capital to public companies.
• The inclusion of anti-dilution provisions and cashless exercise options for warrants is standard practice to protect the investor's interest against future equity issuances or market fluctuations, aligning with terms commonly seen in venture capital or growth equity investments in the biotech space.

Management Changes

Corporate Governance

Legal Proceedings

• The filing states that none of the Reporting Persons or Tianying Yao have been convicted in a criminal proceeding (excluding traffic violations) or were party to a civil proceeding resulting in a judgment enjoining future violations of securities laws in the last five years.
• The company represents that there are no actions by or against the Company or its Subsidiaries or affecting the business or any of the assets of the Company or its Subsidiaries pending before any government entities, or, to the Company's knowledge, threatened to be brought, that would reasonably be expected to have a Material Adverse Effect, except as specifically disclosed in the SEC Documents filed prior to the date of the agreement.

Related Party Transactions

• The transaction itself is a related party transaction, as Huaqin Xue, the sole shareholder of Crystal Peak Holdings Inc. (parent of Crystal Peak Investment Inc.), is the source of funds for the private placement and a reporting person.
• Crystal Peak Investment Inc., a wholly-owned subsidiary of Crystal Peak Holdings Inc., purchased shares and warrants from LakeShore Biopharma Co., Ltd.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the issuance of new shares and warrants. The share purchase price was at a discount, potentially impacting valuation. However, the capital injection could support future growth and value creation.
• Management: Management gains significant capital for operations and growth but faces restrictions on the use of proceeds, requiring approval from the new controlling shareholder for non-core expenditures.
• Employees: The capital infusion could support job security and potential expansion if the core business develops as planned.
• Creditors: The cash injection improves the company's liquidity and financial stability, potentially reducing credit risk.

Next Steps

• The Company shall promptly submit the necessary filing with the China Securities Regulatory Commission (CSRC) in connection with the transactions.
• The Company is obligated to make and keep public information available and file all requisite reports with the SEC to permit the sale of shares pursuant to Rule 144.
• The Reporting Persons intend to continue reviewing their investments in the Issuer and may acquire additional securities or dispose of existing ones based on various market and company-specific factors.

Key Dates

Recommendation

The filing details a significant private placement that provides a substantial capital injection for LakeShore Biopharma, which is a positive for its operations and growth initiatives. The acquisition of a controlling stake by Crystal Peak Investment, backed by Huaqin Xue's personal funds, signals a strong commitment and potential for strategic alignment. However, the transaction also involves immediate dilution for existing shareholders and imposes restrictions on the use of proceeds, ceding some control to the new majority owner. While the capital is beneficial, the terms of the deal (discounted share price, warrant issuance) and the new governance structure warrant a 'hold' recommendation. Investors should monitor how the new capital is deployed and the impact of the new controlling shareholder on the company's strategic direction and financial performance before making further investment decisions. The long-term implications of the new ownership and capital allocation strategy need to be observed.

Keywords

LakeShore Biopharma, Crystal Peak Investment, Private Placement, Warrants, Beneficial Ownership, SEC Filing, Schedule 13D, Biopharma, Equity Investment, Capital Raise, Share Purchase, Corporate Governance, Regulation S, Rule 144